Binding of dimethylarsinous acid to Cys-13α of rat hemoglobin is responsible for the retention of arsenic in rat blood

Meiling Lu, Hailin Wang, Xing Fang Li, Lora L Arnold, Samuel Monroe Cohen, X. Chris Le

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

The metabolism, disposition, and carcinogenicity of arsenic differ dramatically between humans and rats. To understand the molecular basis of these differences, we have characterized arsenic species in rats that were treated with inorganic arsenate (iAsV), monomethylarsonic acid (MMA V), or dimethylarsinic acid (DMAV) for up to 15 weeks. Arsenic significantly accumulated in the red blood cells (RBCs) of rats in the form of hemoglobin (Hb) complexed with dimethylarsinous acid (DMA III), regardless of whether the rats were treated with iAs V, MMAV, or DMAV, suggesting rapid methylation of arsenic species followed by strong binding of DMAIII to rat Hb. The binding site for DMAIII was identified to be cysteine 13 in the α-chain of rat Hb with a stoichiometry of 1:1. Over 99% of the total arsenic (maximum 2.5-3.5 mM) in rat RBCs was bound to Hb for all rats examined (n = 138). In contrast, only 40-49% of the total arsenic (maximum ∼10 μM) in rat plasma was bound to proteins. The ratios of the total arsenic in RBCs to that in plasma ranged from 88-423 for rats that were fed iAsV, 100-680 for rats that were fed MMAV, and 185-1393 for rats that were fed DMAV, when samples were obtained over the 15-week exposure duration. Previous studies have shown an increase in urothelial hyperplasia in rats fed DMAV. This is the first article reporting that treatment with iAsV in the drinking water also produces urothelial hyperplasia and at an even earlier time point than dietary DMAV. Dietary MMA V produced only a slight urothelial response. A correlation between the Hb-DMAIII complex and urothelial lesion severity in rats was observed. The lack of cysteine 13α in human Hb may be responsible for the shorter retention of arsenic in human blood. These differences in the disposition of arsenicals may contribute to the observed differences between humans and rats in susceptibility to arsenic carcinogenicity.

Original languageEnglish (US)
Pages (from-to)27-37
Number of pages11
JournalChemical Research in Toxicology
Volume20
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Arsenic
Rats
Hemoglobins
Blood
Erythrocytes
dimethylarsinous acid
Hyperplasia
Cysteine
Cacodylic Acid
Arsenicals
Plasmas
Methylation
Dynamic mechanical analysis
Metabolism
Stoichiometry
Drinking Water

ASJC Scopus subject areas

  • Toxicology

Cite this

Binding of dimethylarsinous acid to Cys-13α of rat hemoglobin is responsible for the retention of arsenic in rat blood. / Lu, Meiling; Wang, Hailin; Li, Xing Fang; Arnold, Lora L; Cohen, Samuel Monroe; Le, X. Chris.

In: Chemical Research in Toxicology, Vol. 20, No. 1, 01.01.2007, p. 27-37.

Research output: Contribution to journalArticle

@article{148ff28216ce455dbf3c32ef84324df4,
title = "Binding of dimethylarsinous acid to Cys-13α of rat hemoglobin is responsible for the retention of arsenic in rat blood",
abstract = "The metabolism, disposition, and carcinogenicity of arsenic differ dramatically between humans and rats. To understand the molecular basis of these differences, we have characterized arsenic species in rats that were treated with inorganic arsenate (iAsV), monomethylarsonic acid (MMA V), or dimethylarsinic acid (DMAV) for up to 15 weeks. Arsenic significantly accumulated in the red blood cells (RBCs) of rats in the form of hemoglobin (Hb) complexed with dimethylarsinous acid (DMA III), regardless of whether the rats were treated with iAs V, MMAV, or DMAV, suggesting rapid methylation of arsenic species followed by strong binding of DMAIII to rat Hb. The binding site for DMAIII was identified to be cysteine 13 in the α-chain of rat Hb with a stoichiometry of 1:1. Over 99{\%} of the total arsenic (maximum 2.5-3.5 mM) in rat RBCs was bound to Hb for all rats examined (n = 138). In contrast, only 40-49{\%} of the total arsenic (maximum ∼10 μM) in rat plasma was bound to proteins. The ratios of the total arsenic in RBCs to that in plasma ranged from 88-423 for rats that were fed iAsV, 100-680 for rats that were fed MMAV, and 185-1393 for rats that were fed DMAV, when samples were obtained over the 15-week exposure duration. Previous studies have shown an increase in urothelial hyperplasia in rats fed DMAV. This is the first article reporting that treatment with iAsV in the drinking water also produces urothelial hyperplasia and at an even earlier time point than dietary DMAV. Dietary MMA V produced only a slight urothelial response. A correlation between the Hb-DMAIII complex and urothelial lesion severity in rats was observed. The lack of cysteine 13α in human Hb may be responsible for the shorter retention of arsenic in human blood. These differences in the disposition of arsenicals may contribute to the observed differences between humans and rats in susceptibility to arsenic carcinogenicity.",
author = "Meiling Lu and Hailin Wang and Li, {Xing Fang} and Arnold, {Lora L} and Cohen, {Samuel Monroe} and Le, {X. Chris}",
year = "2007",
month = "1",
day = "1",
doi = "10.1021/tx060195+",
language = "English (US)",
volume = "20",
pages = "27--37",
journal = "Chemical Research in Toxicology",
issn = "0893-228X",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Binding of dimethylarsinous acid to Cys-13α of rat hemoglobin is responsible for the retention of arsenic in rat blood

AU - Lu, Meiling

AU - Wang, Hailin

AU - Li, Xing Fang

AU - Arnold, Lora L

AU - Cohen, Samuel Monroe

AU - Le, X. Chris

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The metabolism, disposition, and carcinogenicity of arsenic differ dramatically between humans and rats. To understand the molecular basis of these differences, we have characterized arsenic species in rats that were treated with inorganic arsenate (iAsV), monomethylarsonic acid (MMA V), or dimethylarsinic acid (DMAV) for up to 15 weeks. Arsenic significantly accumulated in the red blood cells (RBCs) of rats in the form of hemoglobin (Hb) complexed with dimethylarsinous acid (DMA III), regardless of whether the rats were treated with iAs V, MMAV, or DMAV, suggesting rapid methylation of arsenic species followed by strong binding of DMAIII to rat Hb. The binding site for DMAIII was identified to be cysteine 13 in the α-chain of rat Hb with a stoichiometry of 1:1. Over 99% of the total arsenic (maximum 2.5-3.5 mM) in rat RBCs was bound to Hb for all rats examined (n = 138). In contrast, only 40-49% of the total arsenic (maximum ∼10 μM) in rat plasma was bound to proteins. The ratios of the total arsenic in RBCs to that in plasma ranged from 88-423 for rats that were fed iAsV, 100-680 for rats that were fed MMAV, and 185-1393 for rats that were fed DMAV, when samples were obtained over the 15-week exposure duration. Previous studies have shown an increase in urothelial hyperplasia in rats fed DMAV. This is the first article reporting that treatment with iAsV in the drinking water also produces urothelial hyperplasia and at an even earlier time point than dietary DMAV. Dietary MMA V produced only a slight urothelial response. A correlation between the Hb-DMAIII complex and urothelial lesion severity in rats was observed. The lack of cysteine 13α in human Hb may be responsible for the shorter retention of arsenic in human blood. These differences in the disposition of arsenicals may contribute to the observed differences between humans and rats in susceptibility to arsenic carcinogenicity.

AB - The metabolism, disposition, and carcinogenicity of arsenic differ dramatically between humans and rats. To understand the molecular basis of these differences, we have characterized arsenic species in rats that were treated with inorganic arsenate (iAsV), monomethylarsonic acid (MMA V), or dimethylarsinic acid (DMAV) for up to 15 weeks. Arsenic significantly accumulated in the red blood cells (RBCs) of rats in the form of hemoglobin (Hb) complexed with dimethylarsinous acid (DMA III), regardless of whether the rats were treated with iAs V, MMAV, or DMAV, suggesting rapid methylation of arsenic species followed by strong binding of DMAIII to rat Hb. The binding site for DMAIII was identified to be cysteine 13 in the α-chain of rat Hb with a stoichiometry of 1:1. Over 99% of the total arsenic (maximum 2.5-3.5 mM) in rat RBCs was bound to Hb for all rats examined (n = 138). In contrast, only 40-49% of the total arsenic (maximum ∼10 μM) in rat plasma was bound to proteins. The ratios of the total arsenic in RBCs to that in plasma ranged from 88-423 for rats that were fed iAsV, 100-680 for rats that were fed MMAV, and 185-1393 for rats that were fed DMAV, when samples were obtained over the 15-week exposure duration. Previous studies have shown an increase in urothelial hyperplasia in rats fed DMAV. This is the first article reporting that treatment with iAsV in the drinking water also produces urothelial hyperplasia and at an even earlier time point than dietary DMAV. Dietary MMA V produced only a slight urothelial response. A correlation between the Hb-DMAIII complex and urothelial lesion severity in rats was observed. The lack of cysteine 13α in human Hb may be responsible for the shorter retention of arsenic in human blood. These differences in the disposition of arsenicals may contribute to the observed differences between humans and rats in susceptibility to arsenic carcinogenicity.

UR - http://www.scopus.com/inward/record.url?scp=33846854172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846854172&partnerID=8YFLogxK

U2 - 10.1021/tx060195+

DO - 10.1021/tx060195+

M3 - Article

VL - 20

SP - 27

EP - 37

JO - Chemical Research in Toxicology

JF - Chemical Research in Toxicology

SN - 0893-228X

IS - 1

ER -